NASDAQ:FEMY Femasys (FEMY) Stock Price, News & Analysis $0.31 -0.05 (-14.22%) Closing price 06/5/2026 04:00 PM EasternExtended Trading$0.30 -0.01 (-3.07%) As of 06/5/2026 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Femasys Stock (NASDAQ:FEMY) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Femasys alerts:Sign Up Key Stats Today's Range$0.29▼$0.3550-Day Range$0.31▼$0.5052-Week Range$0.29▼$1.11Volume2.58 million shsAverage Volume2.08 million shsMarket Capitalization$18.50 millionP/E RatioN/ADividend YieldN/APrice Target$5.33Consensus RatingModerate Buy Company Overview Femasys International, Inc. is a medical device company focused on the research, development and commercialization of innovative technologies for interventional women’s health applications. The company’s core activities center on creating minimally invasive diagnostic and therapeutic products designed to address uterine cavity evaluation and treatment and to improve outcomes in gynecological care. The company’s flagship product, the FemVue® hydrosonography system, is a single-use catheter-based device that enhances visualization of the uterine cavity through saline infusion sonography. This system is intended to facilitate earlier and more accurate diagnosis of intrauterine abnormalities such as polyps, fibroids and adhesions. Femasys is also developing a pipeline of complementary devices aimed at expanding its portfolio of interventional gynecological tools. Femasys is listed on the Nasdaq under the ticker symbol FEMY and is incorporated in Delaware with principal executive offices in Beijing, China. The company’s leadership team includes medical device veterans with deep experience in product development, regulatory affairs and commercial strategy. Femasys continues to pursue regulatory clearances in key markets, including CE marking in Europe, while exploring opportunities to introduce its technologies across Asia, North America and other regions.AI Generated. May Contain Errors. Read More Femasys Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks40th Percentile Overall ScoreFEMY MarketRank™: Femasys scored higher than 40% of companies evaluated by MarketBeat, and ranked 637th out of 868 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingModerate Buy Consensus RatingFemasys has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 3 buy ratings, no hold ratings, and 1 sell rating.Upside PotentialFemasys has a consensus price target of $5.33, representing about 1,640.6% upside from its current price of $0.31.Amount of Analyst CoverageFemasys has only been the subject of 1 research reports in the past 90 days.Read more about Femasys' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Femasys is -1.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Femasys is -1.13, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioFemasys has a P/B Ratio of 3.06. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Femasys' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted3.50% of the float of Femasys has been sold short.Short Interest Ratio / Days to CoverFemasys has a short interest ratio ("days to cover") of 4.28.Change versus previous monthShort interest in Femasys has recently increased by 1.20%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldFemasys does not currently pay a dividend.Dividend GrowthFemasys does not have a long track record of dividend growth. News and Social Media2.5 / 5News Sentiment-0.03 News SentimentFemasys has a news sentiment score of -0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.50 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Femasys this week, compared to 2 articles on an average week.Search Interest7 people have searched for FEMY on MarketBeat in the last 30 days. This is an increase of 40% compared to the previous 30 days.MarketBeat Follows4 people have added Femasys to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Company Ownership1.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Femasys insiders have not sold or bought any company stock.Percentage Held by Insiders7.55% of the stock of Femasys is held by insiders.Percentage Held by Institutions65.27% of the stock of Femasys is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Femasys' insider trading history. Receive FEMY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Femasys and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. FEMY Stock News HeadlinesFemasys Announces 1-for-20 Reverse Stock Split ImplementationJune 5 at 5:10 PM | tipranks.comFemasys Announces 1-for-20 Reverse Stock Split InitiativeJune 4 at 10:11 AM | tipranks.comElon Musk’s $1 Quadrillion AI IPO$1 quadrillion would be enough to send a $2.8 million check to every man, woman, and child in America. That is the scale of what analysts are calling the biggest AI IPO in history.And right now, you can claim a stake before the company goes public, starting with just $500.Elon Musk is predicting this investment could climb 1,000x from here. Early access is available today.June 7 at 1:00 AM | Brownstone Research (Ad)Femasys (FEMY) Stock Forecast & Price TargetMay 19, 2026 | investing.comFemasys Amends Financing Terms and Issues New WarrantsMay 19, 2026 | theglobeandmail.comFemasys updates corporate presentation on women’s health portfolioMay 13, 2026 | tipranks.comFemasys Expands Fertility Care Portfolio in Europe with CE Mark Approval for FemHSG™ CatheterMay 13, 2026 | globenewswire.comFemasys Inc.: Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate UpdateMay 9, 2026 | finanznachrichten.deSee More Headlines FEMY Stock Analysis - Frequently Asked Questions How have FEMY shares performed this year? Femasys' stock was trading at $0.5762 at the start of the year. Since then, FEMY stock has decreased by 46.8% and is now trading at $0.3064. How were Femasys' earnings last quarter? Femasys Inc. (NASDAQ:FEMY) released its quarterly earnings data on Friday, May, 8th. The company reported $0.00 EPS for the quarter, beating analysts' consensus estimates of ($0.07) by $0.07. The company earned $0.42 million during the quarter, compared to the consensus estimate of $0.77 million. Femasys had a negative trailing twelve-month return on equity of 258.08% and a negative net margin of 521.97%. When did Femasys' stock split? Femasys shares reverse split on the morning of Monday, June 8th 2026.The 1-20 reverse split was announced on Thursday, June 4th 2026. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 5th 2026. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Femasys IPO? Femasys (FEMY) raised $34 million in an initial public offering (IPO) on Wednesday, June 16th 2021. The company issued 2,650,000 shares at $12.00-$14.00 per share. Chardan and JonesTrading acted as the underwriters for the IPO. How do I buy shares of Femasys? Shares of FEMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Femasys own? Based on aggregate information from My MarketBeat watchlists, some other companies that Femasys investors own include Sangamo Therapeutics (SGMO), Aurora Cannabis (ACB), Canoo (GOEV), FuelCell Energy (FCEL), Agenus (AGEN), Geron (GERN) and Eos Energy Enterprises (EOSE). Company Calendar Last Earnings5/08/2026Today6/07/2026Next Earnings (Estimated)8/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 FEMY's financial health is in the Yellow zone, according to TradeSmith. FEMY has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryMedical Equipment Current SymbolNASDAQ:FEMY CIK1339005 Webwww.femasys.com Phone770-500-3910FaxN/AEmployees30Year Founded2004Price Target and Rating Average Price Target for Femasys$5.33 High Price Target$8.00 Low Price Target$1.50 Potential Upside/Downside+1,640.6%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage4 Analysts Profitability EPS (Trailing Twelve Months)($0.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$18.63 million Net Margins-521.97% Pretax Margin-500.00% Return on Equity-258.08% Return on Assets-73.72% Debt Debt-to-Equity Ratio0.53 Current Ratio3.91 Quick Ratio1.98 Sales & Book Value Annual Sales$2.29 million Price / Sales8.08 Cash FlowN/A Price / Cash FlowN/A Book Value$0.10 per share Price / Book3.06Miscellaneous Outstanding Shares60,390,000Free Float55,831,000Market Cap$18.50 million OptionableNot Optionable Beta-2.23 Social Links 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:FEMY) was last updated on 6/7/2026 by MarketBeat.com Staff. From Our PartnersJune 12: $100 Turns Into $100,000?The SpaceX IPO is scheduled for June 12, and former tech executive Jeff Brown - who identified Bitcoin, Tesla,...Brownstone Research | Sponsored$30 stock to buy before Starlink goes public (WATCH NOW!)In the next 3 minutes… James Altucher – legendary investor and venture capitalist… And someone who’s kno...Paradigm Press | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredYour book attachedYour Download Link (Expiring) If you still haven't downloaded the free Simple Options Trading For Beginners...Profits Run | SponsoredSpaceX just filed. The clock is ticking.Reuters reports Elon Musk filed secretly. Barron's says it's being finalized behind closed doors. CNBC just re...The Oxford Club | SponsoredSpaceX will mint billionaires. You won't be one of them.By the time a company goes public, 95% of profits have already been made. Insiders bought SpaceX at $20 billio...Behind the Markets | SponsoredRead now. Do not delete. You’ve been warned.Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” P...Porter & Company | SponsoredSpaceX IPO hides a much bigger storyThe SpaceX IPO could be the biggest in history at $1.75 trillion - but the real story isn't the IPO itself. ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Femasys Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Femasys With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
